Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 82, Issue 3, 2003, Pages 287-293

  Dehn, Hannah ^a   Høgdall, Estrid V S ^b   Johansen, Julia S ^c   Jørgensen, Morten ^d   Price, Paul A ^e   Engelholm, Svend A A ^d   Høgdall, Claus K ^a  

^a Rigshospitalet   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ovarian cancer; Prognosis; Tumor marker; YKL 40

Indexed keywords

ENZYME; ENZYME YKL 40; UNCLASSIFIED DRUG; CA 125 ANTIGEN; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; BLOOD; MIDDLE AGED; OVARY TUMOR; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037361965     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2003.00010.x     Document Type: Article

References (34)

1. Gøtrik JK, Hjulsager M. Cancer Incidence in Denmark 1997. Copenhagen, Sundhedsstyrrelsen 1997; 1: 1-81.
2. Kjaer SK, Storm HH. Female genital organs. In: Carstensen, B, Storm, HH, Schou, G, eds. Survival of Danish Cancer Patients 1943-87, Copenhagen. APMIS. Munksgaard 1993 (Suppl. 33), 107-21.
3. Anonymous. Anonymous. Cancer in the Nordic Countries. Copenhagen Assoc Nordic Cancer Registries 1999; 1: 19.
4. Möbus V, Kreienberg R, Crombach G, Würz H, Caffier H et al. Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988; 3: 251-8.
5. Makar AP. Prognostic studies in cancer of the ovary and Fallopian tube with emphasis on the CA 125 antigen and c-erbB-2 oncogene. Acta Obstet Gynecol Scand 1995; 74: 238-40.
6. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-10.
7. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-10.
8. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994; 9: 3417-26.
9. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995; 270: 13076-83.
10. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251: 504-9.
11. Kirkpatrick RB, Matico RE, McNulty DE, Strickler JE, Rosenberg M. An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 1995; 153: 147-54.
12. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992; 7: 501-12.
13. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-5.
14. Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E et al. Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1233-43.
15. Volck B, Price PA, Johansen JS, Sørensen O, Benfield TL et al, YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351-60.
16. Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 203-14.
17. Recklies AD, Baillargeon L, Ling H. HC-gp39 is a growth factor for connective tissue cells. Arthritis Rheum 2000, 43: Abstract, 1686.
18. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001; 285: 926-31.
19. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999; 250: 168-73.
20. Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995; 31A: 1437-42.
21. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999; 38: 618-26.
22. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001; 19: 655-60.
23. Volck B, Ostergaard K, Johansen JS, Garbarsch C, Price PA. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand J Rheumatol 1999; 28: 171-9.
24. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 553-9.
25. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA. YKL-40, a Matrix Protein of Specific Granules in Neutrophils, Is Elevated in Serum of Patients with Community-Acquired Pneumonia Requiring Hospitalization. J Infect Dis 1999; 180: 1722-6.
26. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH et al. Serum YKL-40 is increased in patients with hepatic fibrosis [In Process Citation]. J Hepatol 2000; 32: 911-20.
27. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000; 12: 989-93.
28. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999; 79: 1494-9.
29. Cintin C, Johansen JS, Christensen I, Price P, Sørensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal cancer is related to short survival. Cancer 2002.
30. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M et al. Chondrex: new marker of joint disease. Clin Chem 1998; 44: 509-16.
31. Høgdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Høgdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Laboratory Invest 2000; 60: 247-51.
32. Cruickshank DJ, Paul J, Lewis CR, McAllister EJ, Kaye SB. An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer. Br J Cancer 1992; 65: 597-600.
33. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207-12.
34. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995; 58: 42-7.